Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES 简体中文 中文 हिन्दी HI
Sign Up
Log in
Eagle Pharmaceuticals Inc banner

Eagle Pharmaceuticals Inc
OTC:EGRX

Watchlist Manager
Eagle Pharmaceuticals Inc Logo
Eagle Pharmaceuticals Inc
OTC:EGRX
Watchlist
Price: 0.95 USD Market Closed
Market Cap: $12.3m
Write Note Create Alert

Wall St Price Targets

EGRX Price Forecast
No price targets yet

We don't have analyst price targets for EGRX yet.

EGRX Analyst Rating
Based on 1 analyst

avg. 5 of 5
Strong buy
1 100%
Buy
0 0%
Hold
0 0%
Sell
0 0%
Strong sell
0 0%

The analyst rating for EGRX is Strong buy.

Eagle Pharmaceuticals Inc Competitors:
Price Targets

Financial Estimates

Past growth per year

Average annual growth cannot be calculated for these periods.

Explore analyst estimates, growth and forecast ranges.

Reported Lowest–highest estimate

Continue EGRX Research

Summary
EGRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
EGRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EGRX stock valuation using valuation multiples.
Wall St Estimates
EGRX price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financial Statements
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EGRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financial Statements
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is EGRX's stock price target?
Not Available

EGRX does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Eagle Pharmaceuticals Inc?
Projected CAGR
-10%

Over the last 10 years, the compound annual growth rate for Revenue has been 62%. The projected CAGR for the next 3 years is -10%.

What is the Operating Income forecast for Eagle Pharmaceuticals Inc?
Projected CAGR
-21%

The compound annual growth rate for Operating Income over the next 3 years is -21%.

Back to Top
ALPHA SPREAD
Follow us
Join 363,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.